When analysing characteristics per tumour, the molecular subtypes consisted of hormone receptor-positive human epidermal growth factor receptor 2 (HER-2)-negative in 55% (n = 11/20), HER-2-positive in 30% (n = 6/20), and triple-negative in 15% (n = 3/20). This evidence concerns the gene ERBB2 and neoplasm.